Literature DB >> 6231358

Chlamydia trachomatis as a cause of pneumonitis and pleural effusion.

H R Stutman, P J Rettig, S Reyes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6231358     DOI： 10.1016/s0022-3476(84)80554-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  9 in total

1.  Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge.

Authors:  Delia F Tifrea; Sukumar Pal; Deana N Toussi; Paola Massari; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-08-30       Impact factor: 2.700

2.  Protection against a chlamydial respiratory challenge by a chimeric vaccine formulated with the Chlamydia muridarum major outer membrane protein variable domains using the Neisseria lactamica porin B as a scaffold.

Authors:  Delia F Tifrea; Sukumar Pal; Jeff Fairman; Paola Massari; Luis M de la Maza
Journal:  NPJ Vaccines       Date:  2020-05-08       Impact factor: 7.344

3.  Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine.

Authors:  Delia F Tifrea; Guifeng Sun; Sukumar Pal; Gustavo Zardeneta; Melanie J Cocco; Jean-Luc Popot; Luis M de la Maza
Journal:  Vaccine       Date:  2011-05-06       Impact factor: 3.641

4.  Chlamydial infections in children: a seroepidemiological study.

Authors:  J Gray; B Hovelius; P A Mårdh
Journal:  Eur J Clin Microbiol       Date:  1986-10       Impact factor: 3.267

5.  A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge.

Authors:  Chunmei Cheng; Sukumar Pal; Delia Tifrea; Zhenyu Jia; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-11-27       Impact factor: 2.700

6.  Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis.

Authors:  Delia F Tifrea; Pooja Ralli-Jain; Sukumar Pal; Luis M de la Maza
Journal:  Infect Immun       Date:  2013-03-11       Impact factor: 3.441

7.  A study of the incidence of urogenital Chlamydia trachomatis in patients attending specialized departments of Rome, Milan and Turin, Italy.

Authors:  M Del Piano; E M Magliano; M A Latino; R Nicosia; R Sessa; P Clerici; R Colombo; C Gordini; A Serio
Journal:  Eur J Epidemiol       Date:  1992-07       Impact factor: 8.082

8.  Protection against a chlamydial respiratory challenge by a chimeric vaccine formulated with the Chlamydia muridarum major outer membrane protein variable domains using the Neisseria lactamica porin B as a scaffold.

Authors:  Delia F Tifrea; Sukumar Pal; Jeff Fairman; Paola Massari; Luis M de la Maza
Journal:  NPJ Vaccines       Date:  2020-05-08       Impact factor: 7.344

9.  Protection of outbred mice against a vaginal challenge by a Chlamydia trachomatis serovar E recombinant major outer membrane protein vaccine is dependent on phosphate substitution in the adjuvant.

Authors:  Sukumar Pal; Salvador Fernando Ausar; Delia F Tifrea; Chunmei Cheng; Scott Gallichan; Violette Sanchez; Luis M de la Maza; Lucian Visan
Journal:  Hum Vaccin Immunother       Date:  2020-03-02       Impact factor: 3.452
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.